NCT06924125 Spanish Natural History Study for LAMA2 Muscular Dystrophy
| NCT ID | NCT06924125 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute |
| Condition | LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A) |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2021-07-27 |
| Primary Completion | 2030-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2021-07-27 with a primary completion date of 2030-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this natural history study is to comprehensively characterize the disease progression and clinical features of LAMA2-related dystrophies (LAMA2-RD) in the pediatric population. The study aims to establish a well-defined cohort of patients in Spain, enabling long-term follow-up and facilitating recruitment for future clinical trials.
Eligibility Criteria
Inclusion Criteria: * All patients with compatible clinical presentation and identification of 2 pathogenic variants in LAMA2, or muscle biopsy with decreased laminin alpha2 protein and at least one pathogenic variant * Signed informed consent by the Legal Authority Responsible and/or assent by the subject (starting from 6 years old)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06924125 clinical trial?
This trial is open to participants of all sexes, aged 0 Minutes or older, up to 100 Years, studying LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06924125 currently recruiting?
Yes, NCT06924125 is actively recruiting participants. Contact the research team at david.gomezandres@vallhebron.cat for enrollment information.
Where is the NCT06924125 trial being conducted?
This trial is being conducted at Barcelona, Spain.
Who is sponsoring the NCT06924125 clinical trial?
NCT06924125 is sponsored by Hospital Universitari Vall d'Hebron Research Institute. The trial plans to enroll 100 participants.